What is CRISPR Therapeutics?
Founded in 2013 and headquartered in Zug, Switzerland, CRISPR Therapeutics is a leading developer of gene-based medicines. The company focuses on targeting diseases at the molecular level, leveraging cutting-edge CRISPR/Cas9 gene-editing technology. Its mission is to develop transformative therapies for serious diseases, addressing unmet medical needs across various therapeutic areas. The company's scientific foundation is built on pioneering research in gene editing, positioning it at the forefront of genetic medicine innovation.
How much funding has CRISPR Therapeutics raised?
CRISPR Therapeutics has raised a total of $56M across 1 funding round:
Stock Offering
$56M
Stock Issuance/Offering (2016): $56M, investors not publicly disclosed
What's next for CRISPR Therapeutics?
With the recent influx of capital, CRISPR Therapeutics is poised to accelerate its research and development pipeline, potentially advancing its lead programs towards clinical trials and commercialization. This strategic investment will likely fuel further expansion of its scientific team and enhance its capabilities in gene editing technology. The company's focus on developing novel therapies for a range of genetic disorders suggests a trajectory aimed at addressing significant global health challenges and capturing a substantial share of the rapidly growing gene therapy market.
See full CRISPR Therapeutics company page
